1,143 karma · joined November 22, 2008
Same here. A good case for why a more a faithful adaptation doesn't make for a better product. You believe in the world Lynch creates. The miniseries, by contrast, is so fake looking and fake feeling that you can't suspend disbelief.
You can run a company for quite a while on $110M, even in Silicon Valley.
Am I missing something?
(This doesn't imply I think the American system is working. On the contrary, I think it's a mess.)
They were actively testing people in Arizona for at least several months. Definitely NOT in "research phase"
People who work at companies that come under its umbrella wish that were true. It's not. There is a revolving door and a lot of pressure back and forth but the relationship is a lot more complicated than "pharma owns the FDA". There are some fire-breathing regulators there (who think they're the only thing preventing Big Pharma from selling us poison) who would slap your face if you told them that.
Class III devices (pacemakers, deep brain stimulators, insulin pumps)
> Did the FDA actually check your software or just your documentation?
In a submission, occasionally. In an audit, it depended on the nature of an audit. I've been part of one audit that was due to persistent SW failure and yes, they checked code.
> Did you find the process of writing documentation instrumental in ensuring that your software was carefully tested?
No, but that's not really the point of documentation.
> Did you ensure that your tests were reproducible and comprehensive?
Yes, we could kill people if we screwed something up.
> They were more concerned with making sure signatures and dates were correct and that our documentation didn't make us look bad.
This practice is common, I grant. Doesn't mean it's universal or right.
> The FDA doesn't really give a damn about what I really worked on, do they?
FDA heavily triages activity based on risk. If your product is life-sustaining they will definitely be all up in your business.
Personally I've always had a strict salary/comp band in place for each position, but having never had a company with > 25 people, I wonder at what point that breaks down.
To summarize regulatory action:
Theranos sent in a marketing application to FDA for one of the use of Edison with one test, FDA said OK, this looks good based on the data you sent us (FDA can only see what you send them). FDA then placed Theranos on an audit list (common practice for any new company), stopped by after a few months, and found out that Theranos' own internal procedures for making sure that the data they generate about their product's performance is honest were, shall we say, poor. They also found Theranos marketing other components that they had not sought clearance to market from FDA. So FDA issued a 483 (deficiency notice) and the fallout from that we have yet to see. (I personally think there will be another shoe to drop here.)
Now, on the lab side, which is regulated by the Center for Medicare and Medicaid Systems, not FDA, the process is different. Basically CMS allows you to get a preliminary certificate after a cursory inspection and gives you 2 years within which to build a real testing process and get your shit together before they do the real audit. Theranos's Bay Area lab got the preliminary certificate and massively failed the real audit, and then massively failed to fix anything, which is what's landing Holmes in potentially very hot water (being banned from the diagnostic industry for two years in the US). The reason this is structured this way is that 1) to have enough data for a meaningful audit takes time and 2) the government expects anyone contracting with a brand new lab for the first two years to understand that it's a brand new lab and act accordingly (i.e. be skeptical, do your own audit, don't take NewCo's evidence at face value).
Most people in the industry understand this. Hell, most people at Walgreens understood this and were properly skeptical [1]. But the top execs at the time overrode the valid concerns of their QC people in order to chase the unicorn.
[1] http://www.wsj.com/articles/craving-growth-walgreens-dismiss...
Which you and I know are especially illegal in the life science industries at the federal and state (in most states) levels. But given how secretive Holmes was toward potential investors and customers this would not surprise me.
Yes, there is definitely lack of competition at the provider level which has gotten worse post-ACA. But in this context I'm talking about lack of competition among technology manufacturers. Really easy to set high prices for things when competitors can't enter your market without going through several hoops. That's how you get guys like Martin Shkreli.
“There have been massive recalls of single tests in the past, but I’m not aware of one where a company recalled the entirety of the results from its testing platform,” said Geoffrey Baird, associate professor in the department of laboratory medicine at the University of Washington in Seattle. “I believe that’s unprecedented.”
Based on my ~10 years experience in device/diagnostic industry, I concur with this assessment. I don't think anything at this scale has ever happened. There are only two reasons a diagnostic company would issue such a sweeping retraction of test results:
- The product just plain doesn't work
- The administration of the product (lab procedures, etc) was so shoddy that accuracy can't be guaranteed.
Either of those conclusions is damning. Generally a company tries to limit the scope of the damage, either by scoping for type of test, i.e. "Oh well Edison is fine, but this this particular test (say cholesterol) is failing. The other tests are fine though" or scoping for time "We had some poor lab procedures from September thru December but we cleaned house and we're all better now". The WSJ report implies they did neither.